New frontiers
Between 2013 and 2026, three things changed in natural-product science: long plant pathways were rebuilt in yeast and in tobacco leaves, genome mining and molecular networking turned sequence and spectra into searchable chemistry, and a handful of plant- and fungus-derived compounds reached late-phase registered trials. Each entry below is tied to the paper or record that reports it.
Status. This page reports other groups' published work and public registry records, read on October 28, 2026. EUTECNIQ has no laboratory, no strains, no data and no trials; the closing paragraph is a proposal.
What changed since 2013
Two lines of work carried most of the change. Pathways that plants run over many enzymatic steps were refactored into microbial and plant hosts, and the tools that assign structures to genes and to spectra were released openly and kept growing.
| Year | Advance | What the paper reports | Primary paper (DOI) |
|---|---|---|---|
| 2013 | Artemisinic acid in yeast | Fermentation titer of 25 g/L artemisinic acid in engineered S. cerevisiae, plus a chemical route to artemisinin using a chemical source of singlet oxygen | Paddon et al., Nature 496:528–532. 10.1038/nature12051 |
| 2013 | Natural deep eutectic mixtures | More than 100 natural deep eutectic mixtures formed from plant primary metabolites | Dai et al., Anal Chim Acta 766:61–68. 10.1016/j.aca.2012.12.019 |
| 2016 | GNPS | Open-access knowledge base for raw, processed and identified MS/MS data, with community reference libraries and continuous reanalysis of deposited data | Wang et al., Nat Biotechnol 34:828–837. 10.1038/nbt.3597 |
| 2019 | Cannabinoids in yeast | Complete biosynthesis of five cannabinoid acids in S. cerevisiae from galactose, and analogues from fed fatty acids | Luo et al., Nature 567:123–126. 10.1038/s41586-019-0978-9 |
| 2019 | SIRIUS 4 | Molecular formula and structure identification from tandem mass spectra, with identification rates above 70% on the reported metabolomics datasets | Dührkop et al., Nat Methods 16:299–302. 10.1038/s41592-019-0344-8 |
| 2021 | CANOPUS | Compound-class prediction for 2,497 classes from fragmentation spectra, with an average cross-validation accuracy of 99.7% on reference data | Dührkop et al., Nat Biotechnol 39:462–471. 10.1038/s41587-020-0740-8 |
| 2022 | Vindoline and catharanthine in yeast | De novo production of both vinblastine precursors: 30 enzymatic steps beyond native metabolites, 56 genetic edits, 34 heterologous genes | Zhang et al., Nature 609:341–347. 10.1038/s41586-022-05157-3 |
| 2023 | antiSMASH 7 | Detectable cluster types raised from 71 to 81, with added chemical-structure prediction and cluster-regulation analysis | Blin et al., Nucleic Acids Res 51:W46–W50. 10.1093/nar/gkad344 |
| 2024 | QS-21 in yeast | Complete biosynthesis of the saponin adjuvant QS-21 and derivatives, requiring balanced expression of 38 heterologous enzymes from six organisms across seven enzyme families | Liu et al., Nature 629:937–944. 10.1038/s41586-024-07345-9 |
| 2024 | MIBiG 4.0 | 3,059 curated gene-cluster entries after 557 new and 590 modified entries, from 8,304 edits by 267 contributors | Zdouc et al., Nucleic Acids Res 53:D678–D690 (published December 2024, 2025 issue). 10.1093/nar/gkae1115 |
| 2025 | Baccatin III in a plant host | Seven newly resolved genes allow a 17-gene de novo route to baccatin III in N. benthamiana leaves, at levels the authors call comparable with natural abundance in Taxus needles | McClune et al., Nature 643:582–592. 10.1038/s41586-025-09090-z |
| 2025 | antiSMASH 8 | Detectable cluster types raised from 81 to 101, with improved terpenoid and tailoring-enzyme analysis | Blin et al., Nucleic Acids Res 53:W32–W38. 10.1093/nar/gkaf334 |
Titles, journals, volumes and reported quantities read from each article record and abstract, October 28, 2026.
Pathways rebuilt in hosts
A pathway moves into a host when every enzyme in it is known, expressed and balanced. The published cases differ in how much of the molecule the host makes: some end at a precursor that chemistry finishes, and the reported scale ranges from fermenter titers to leaf-level isolation.
| Target | Host | Pathway size, as reported | What the host produced | Source |
|---|---|---|---|---|
| Artemisinin | S. cerevisiae | Complete pathway to artemisinic acid, including a plant dehydrogenase and a second cytochrome described in the paper | Artemisinic acid at 25 g/L; artemisinin made from it chemically | Paddon 2013 |
| Cannabinoid acids | S. cerevisiae | Native mevalonate pathway engineered, plus a multi-organism hexanoyl-CoA route and Cannabis genes | Five cannabinoid acids from galactose, plus analogues from fed fatty acids | Luo 2019 |
| Vinblastine precursors | S. cerevisiae | 30 enzymatic steps beyond native metabolites; 56 genetic edits; 34 heterologous genes; 10 yeast genes altered | Vindoline and catharanthine; vinblastine by chemical coupling in vitro | Zhang 2022 |
| QS-21 | S. cerevisiae | 38 heterologous enzymes from six organisms, across seven enzyme families, with plant compartmentalization mimicked in yeast | QS-21, its precursors and structural analogues | Liu 2024 |
| Baccatin III | N. benthamiana | 17 genes, of which seven were newly resolved, plus the NTF2-like protein FoTO1 and a β-phenylalanine-CoA ligase | Baccatin III isolated from leaves; also 3′-N-debenzoyl-2′-deoxypaclitaxel | McClune 2025 |
Entries restate each paper's own abstract; DOIs in the table above. A reported titer is a laboratory or pilot result, not a cost of goods.
Long pathways are now reachable, but each case still ends in chemistry, purification and a supply decision.
Notes and sources
QS-21 is relevant beyond the laboratory: the adjuvant AS01B in the licensed recombinant zoster vaccine is composed of monophosphoryl lipid A and QS-21, "a saponin purified from Quillaja saponaria Molina plant extract", at 50 mcg per 0.5 mL dose (FDA-approved prescribing information, revised February 2026; initial U.S. approval 2017). The 2024 paper states that QS-21 "remains the only saponin-based adjuvant that has been clinically approved for use in humans" and that supply depends on extraction from the tree or low-yielding total synthesis. Nothing on this page claims that any yeast-made material has been used in a licensed product.
Cells instead of bark
The precedent for making a plant drug without the plant is older than the yeast work. Plant cell fermentation grows a selected Taxus cell line in aqueous medium in fermentation tanks, and the award record states what it removed from the previous semisynthetic route.
| Item | Figure as published |
|---|---|
| Paclitaxel in Pacific yew bark | About 0.0004% by weight |
| 10-DAB in European yew leaves and twigs | About 0.1% by dry weight; carries 8 of the chiral centers |
| Semisynthesis from 10-DAB | 11 chemical transformations, 7 isolations, 13 solvents and 13 organic reagents and other materials |
| Published total syntheses | About 40 steps, overall yield about 2% |
| Plant cell fermentation route | No chemical transformations, so six intermediates eliminated; ten solvents and six drying steps eliminated |
| Projected materials avoided, first five years | About 71,000 pounds of hazardous chemicals and other materials |
U.S. EPA, Presidential Green Chemistry Challenge: 2004 Greener Synthetic Pathways Award (Bristol-Myers Squibb Company), agency page read October 28, 2026. Figures are the award record's, including its projections.
Clusters you can search
Bacterial and fungal specialized metabolites are usually encoded by clustered genes, so a genome can be screened for chemistry before anything is grown. Two releases set the pace: a detector that covers more cluster types with each version, and a curated repository that records what a cluster makes.
| Resource | Release | Counts as stated | What it does |
|---|---|---|---|
| antiSMASH | Version 7 (2023) | 81 cluster types | Detects and annotates biosynthetic gene clusters in bacterial, archaeal and fungal genomes; web server and open-source tool |
| antiSMASH | Version 8 (2025) | 101 cluster types | Adds terpenoid and tailoring-enzyme analysis and further work on modular polyketide synthases and nonribosomal peptide synthetases |
| MIBiG | Version 4.0 (published December 2024) | 3,059 curated entries; 557 new, 590 modified; 8,304 edits; 267 contributors | Standardized, machine-readable records of characterized clusters and their products, with a peer-review model for submissions |
antiSMASH 7 and 8, and MIBiG 4.0 release papers (DOIs in the overview table). MIBiG began in 2015.
Cluster detection is strongest for bacteria and fungi; plant pathways are generally not clustered, which is why the plant cases above needed transcriptional work to find their genes.
Spectra into structures
Untargeted mass spectrometry finds thousands of features in an extract, and most of them match nothing in a library. Three open tools narrowed that gap: a shared spectral knowledge base with molecular networking, a formula-and-structure engine, and a classifier that assigns a compound class when no structure can be named.
| Tool | Output | Reported performance | Paper |
|---|---|---|---|
| GNPS | Shared MS/MS libraries; molecular networking that groups spectra by similarity; continuous reanalysis of deposited data | No single figure; the paper describes the infrastructure and community curation | Wang 2016 |
| SIRIUS 4 | Molecular formula, then structure search against databases through CSI:FingerID | Identification rates above 70% on the datasets reported | Dührkop 2019 |
| CANOPUS | Compound class for a spectrum, including classes with no tandem-MS training data | 2,497 classes; average cross-validation accuracy 99.7% on reference data | Dührkop 2021 |
Reported values are those stated in each paper's abstract; cross-validation accuracy is not the same as accuracy on new samples.
Related: how targeted and untargeted analysis differ, with a worked molecular network · analytical methods
What the reviews claim
Peer-reviewed reviews, not vendor material, are the defensible source here. Two of them set out the same conclusion: the computational methods are available, and the binding constraint is data quality and validation rather than algorithms.
| Review | Scope | Stated limit |
|---|---|---|
| Mullowney et al., Nat Rev Drug Discov 2023;22:895–916 | Computational omics combined with machine learning for activity prediction and de novo design applied to natural products | States the need for high-quality datasets to train deep-learning algorithms and for appropriate strategies to validate algorithms |
| Atanasov et al., Nat Rev Drug Discov 2021;20:200–216 | Analytical tools, genome mining and engineering, and microbial culturing advances | Describes technical barriers to screening, isolation, characterization and optimization that reduced industry interest from the 1990s |
| Newman and Cragg, J Nat Prod 2020;83:770–803 | Sources of approved drugs from January 1981 to September 2019, with a category for FDA-recognized botanical defined mixtures | A classification review of approvals, not a prediction of future output |
DOIs: 10.1038/s41573-023-00774-7; 10.1038/s41573-020-00114-z; 10.1021/acs.jnatprod.9b01285. Read October 28, 2026.
Related: what a botanical model would need to be trained on · the paired data a laboratory would have to generate · computational methods in use
Two frontiers covered elsewhere
Two active areas are treated in full on their own pages, so they are only placed in time here. Natural deep eutectic solvents were described in 2013 as a class of more than 100 mixtures of plant primary metabolites; the extraction page sets out what they can and cannot yet do, including the regulatory position. Delivery systems are judged by measured pharmacokinetics, not by particle size.
Read instead: deep eutectic solvents, solvent limits and recovery · delivery systems and what a bioavailability study must show · absorption, distribution, metabolism and excretion
Compounds in late-phase trials
A compound is listed here only if a phase 3 record exists on ClinicalTrials.gov. The table reports registry fields: phase, status, sponsor, enrollment and dates. It reports no results and no efficacy, and registration is not approval.
| Record | Intervention as described | Phase and status | Sponsor (class) | Enrollment | Start |
|---|---|---|---|---|---|
| NCT04993729 | T89 capsule, described in the record as "a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi" | Phase 3; completed | Tasly Pharmaceuticals, Inc. (industry) | 853 (actual) | July 21, 2021 |
| NCT07426120 | Botanical total coumarin cream, applied topically, against a vehicle cream | Phase 3; recruiting | Psoriasis Research Institute of Guangzhou (industry) | 300 (estimated) | February 1, 2026 |
| NCT05624268 | COMP360 psilocybin, single administration | Phase 3; completed | COMPASS Pathways (industry) | 258 (actual) | January 24, 2023 |
| NCT05711940 | COMP360 psilocybin, two administrations | Phase 3; active, not recruiting | COMPASS Pathways (industry) | 572 (actual) | February 14, 2023 |
| NCT06308653 | Psilocybin 25 mg or 5 mg, stated in the record to be synthetically manufactured | Phase 3; active, not recruiting | Usona Institute (other) | 238 (actual) | March 13, 2024 |
| NCT07226232 | Psilocybin, two doses compared | Phase 3; recruiting | VA Office of Research and Development (federal) | 240 (estimated) | August 3, 2026 |
ClinicalTrials.gov API v2 records, retrieved October 28, 2026. Every record above is flagged in the registry as an FDA-regulated drug study. "Results posted" was false for all six on that date.
Regulatory status, stated precisely. Psilocybin is listed as a Schedule I hallucinogenic substance at 21 CFR 1308.11(d)(29), drug code 7437. A query of Drugs@FDA through the openFDA drug application endpoint on October 28, 2026 returned no approved application with psilocybin as an active ingredient. FDA's guidance Psychedelic Drugs: Considerations for Clinical Investigations (docket FDA-2023-D-1987) is final and dated July 2026; it finalizes a draft issued in 2023. A phase 3 registration means a trial exists, not that a product is approved or that any benefit is established.
Notes and sources
Botanical drug development has its own FDA guidance, Botanical Drug Development (final, December 2016, docket FDA-2000-D-0103), which covers investigational new drug applications and new drug applications for botanical products. The two botanical records above are both multi-component plant preparations, which is the case that guidance addresses. Sponsor class ("industry", "other", "federal") is the registry's own field.
Filter the advances
The same items, arranged by kind against a year axis. Choose a kind to bring its markers forward; the rest stay in place, dimmed, so the timing can still be compared.
All 19 items shown.
Where EUTECNIQ would work
Proposed EUTECNIQ would not rebuild pathways. It would work where these advances meet a product decision: untargeted analysis to characterize an extract, open cluster and spectral resources to read the literature against a lot, and paired laboratory records so that any model it later used could be tested. No strain engineering, no clinical sponsorship.
Related pages: Large Botanical Model · Data asset · From plant to prescription · Discovery and characterization · Clinical research
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.